Alnylam Pharmaceuticals collaborates with Alliance for Genomic Discovery, broadening a diverse clinical genomic database to fuel precision medicine development
In a significant move, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has joined the Alliance for Genomic Discovery (AGD) as a member. This partnership is expected to add 31,250 whole-genomes to the AGD's clinical genomic database, further enriching its resources.
The AGD, an alliance that includes participants engaged in the Earth Biogenome Project and other European reference genome initiatives, aims to create high-resolution reference genomes for all eukaryotic organisms on Earth. With Alnylam on board, the AGD's clinical genomic database now boasts over 281,250 whole-genome cohorts, a significant milestone in its mission.
Alnylam, a pioneer in RNA interference (RNAi) therapeutics, aims to use human genetics to guide them as they discover and develop potential life-changing medicines. The company's goal is to harness the power of RNAi therapeutics, which function by 'silencing' genes that cause or contribute to disease.
The addition of Alnylam's data to the AGD's clinical genomic database will prove invaluable to Alnylam scientists, providing a rich resource for them to hunt for new therapeutic targets. The AGD's dataset is already showing its worth, with novel therapeutic targets, particularly in autoimmune and neurodegenerative diseases, being identified or validated.
However, it's important to note that the release contains forward-looking statements that involve risks and uncertainties. Challenges in researching, developing, and launching new technologies, and the challenges associated with multiparty collaborations, could potentially impact the results. The Securities and Exchange Commission filings of the company contain further details on these factors.
Nashville Biosciences LLC (NashBio), a for-profit subsidiary of Vanderbilt University Medical Center, is another key player in this sphere. NashBio focuses on making complex healthcare data accessible for various life science research and development applications. To stay updated on NashBio's contact information and updates, visit their website NashBio.com, LinkedIn, or their Twitter handle @NashvilleBio.
Illumina, a global leader in DNA sequencing and array-based technologies, is another vital partner in the AGD. Illumina serves customers in various markets such as life sciences, oncology, reproductive health, agriculture, and others. You can find Illumina on various social media platforms including LinkedIn, Instagram, TikTok, Facebook, and YouTube. For contact information for Illumina Investors, visit [email protected], and for media inquiries, contact [email protected].
As the AGD continues to grow and evolve, it's clear that its comprehensive clinical genomic dataset will continue to be a valuable resource for researchers and pharmaceutical companies alike. The partnership between Alnylam and the AGD is just one example of how collaborative efforts can drive innovation and accelerate the discovery of new therapeutic targets.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
